MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback